Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $80.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 230.72% from the company’s previous close.
Other equities research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Friday, July 17th. Bank of America reaffirmed a “buy” rating and set a $47.00 price objective on shares of Beam Therapeutics in a research note on Wednesday, July 8th. Wall Street Zen raised Beam Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. Wedbush reissued an “outperform” rating and issued a $65.00 target price on shares of Beam Therapeutics in a research note on Wednesday, October 14th. Finally, William Blair raised Beam Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.10.
Read Our Latest Analysis on Beam Therapeutics
Beam Therapeutics Trading Up 3.1%
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.07). Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%. The company had revenue of $0.49 million for the quarter, compared to analyst estimates of $16.37 million. During the same period last year, the firm earned ($1.00) earnings per share. The firm’s revenue for the quarter was down 94.2% on a year-over-year basis. Sell-side analysts anticipate that Beam Therapeutics will post -4.49 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider Amy Simon sold 16,667 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $25.74, for a total transaction of $429,008.58. Following the completion of the sale, the insider directly owned 85,696 shares of the company’s stock, valued at approximately $2,205,815.04. This represents a 16.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Evans sold 25,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total value of $589,250.00. Following the sale, the chief executive officer directly owned 1,047,205 shares of the company’s stock, valued at approximately $24,682,621.85. The trade was a 2.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.80% of the stock is currently owned by corporate insiders.
Institutional Trading of Beam Therapeutics
A number of large investors have recently bought and sold shares of BEAM. Versant Capital Management Inc increased its stake in Beam Therapeutics by 123.6% during the 3rd quarter. Versant Capital Management Inc now owns 1,239 shares of the company’s stock worth $30,000 after purchasing an additional 685 shares in the last quarter. Hollencrest Capital Management bought a new stake in Beam Therapeutics during the 1st quarter worth approximately $43,000. Northwestern Mutual Wealth Management Co. bought a new stake in Beam Therapeutics during the 2nd quarter worth approximately $43,000. Nykredit A S bought a new stake in Beam Therapeutics during the 2nd quarter worth approximately $75,000. Finally, Purpose Unlimited Inc. bought a new stake in Beam Therapeutics during the 4th quarter worth approximately $80,000. 99.68% of the stock is owned by institutional investors.
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines using base editing, a technology designed to make targeted changes to DNA without cutting both strands of the DNA double helix. The company’s platform is intended to address diseases caused by specific genetic mutations and to support the development of potentially durable treatments.
Beam’s research and development activities focus on areas including hematology, liver diseases and genetic disorders.
Recommended Stories
- Five stocks we like better than Beam Therapeutics
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
